
    
      Subjects who completed the prospective baseline periods and meet met the prespecified entry
      criteria will be randomized into 2 groups: acupuncture treatment, and topiramate treatment
      group.

      Subjects will be allowed to continue taking acute migraine medications for the treatment of
      breakthrough attacks during the trial, but any migraine preventive medications will be
      prohibited.

      Written informed consent was obtained from all participants before entering the study.
    
  